Skip to Content
Jump to the top of the page

The Eimen Kaminski Group

William Blair Private Wealth Management

The Eimen-Kaminski Team

About William Blair

William Blair is a premier global partnership with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 30 offices worldwide.*

  • 1935

    Year William Blair was founded

  • 1,950+

    Employees worldwide

  • 154 billion+

    Client assets

  • 90+ Years

    Independent and employee-owned

  • 30+

    Offices worldwide*

  • 650+

    Companies under coverage

As of December 31, 2025
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Equity.

More about William Blair affiliated entities

Thought Leadership

  • 2026 Wealth Planning and Philanthropy Strategies

    As we kick off 2026, now is the time to review your financial strategy and position yourself for success in the year ahead.

    Read more
  • Game pieces on a board

    Thinking Strategically About Charitable Giving

    Using charitable giving strategies to enhance the tax-efficiency of your donations plays a vital role in maximizing the impact of your gifts.

    Read more
  • Keeping Your Financial Information Secure—And Steps to Take if You Have Been Hacked

    As the world becomes more digitally connected, cybersecurity risks will keep rising. Explore our guide to help you keep your financial information secure, recognize digital risks, and identify the next steps to take if your data has been compromised.

    Read more

Our Latest News

  • BUNN Has Been Acquired by Ali Group

    William Blair acted as the exclusive financial advisor to BUNN Commercial LP, in connection with its sale to Ali Group.

    Read more
  • BridgeBio Pharma, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of BridgeBio Pharma, Inc. (BBIO $65.36), a commercial-stage biotech company focused on developing medicines for genetic conditions. With this initiation, senior research associate John Boyle, Ph.D. and analyst Myles Minter, Ph.D. have expanded and deepened William Blair’s existing biotechnology coverage.

    Read more
  • Jade Biosciences, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Jade Biosciences, Inc. (JBIO $14.05), a clinical-stage biotechnology company focused on developing novel biologics for the treatment of autoimmune diseases.

    Read more

Ready to start a conversation? Contact us today.

This content is for informational and educational purposes only and not intended as investment advice or a recommendation to buy or sell any security. Investment advice and recommendations can be provided only after careful consideration of an investor's objectives, guidelines, and restrictions.

Copyright © 2025 William Blair & Company, L.L.C. | Privacy Terms

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures